Population-based analysis of normal Total PSA and percentage of free/Total PSA values: results from screening cohort
- PMID: 19376563
- DOI: 10.1016/j.urology.2008.10.026
Population-based analysis of normal Total PSA and percentage of free/Total PSA values: results from screening cohort
Abstract
Objectives: To examine the distribution of total prostate-specific antigen (tPSA) and percentage of free/total PSA (%f/tPSA) values in patients undergoing prostate cancer screening in Canada.
Methods: The data from 4 consecutive annual prostate cancer screening events held in Montreal, Canada were examined with respect to age, tPSA, and %f/tPSA in 3222 men.
Results: Within the entire cohort, the median PSA level was 1.0 ng/mL and the median %f/tPSA was 26%. Using the interquartile range around the median, the upper bound for tPSA was situated at 1.9 ng/mL and the lower bound for %f/tPSA was at 19%. The 90th percentile for the median tPSA was 3.8, and the 10th percentile for the median %f/tPSA was 14. PSA and %f/tPSA showed a relation with age. The 75th percentile for the median tPSA level in the age category 40-49, 50-59, 60-69, and 70-79 years was 1.1, 1.4, 2.6, and 3.6 ng/mL, respectively. The 25th percentile for the median %f/tPSA level in the age category 40-49, 50-59, 60-69, and 70-79 years was 19, 21, 18 and 19 ng/mL, respectively.
Conclusions: Our results can guide clinicians regarding the population-based distribution of serum tPSA and %f/tPSA values. Those values can be used for the purpose of counseling, as well as in the informed consent process before prostate biopsy.
Similar articles
-
Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.BJU Int. 2007 Jul;100(1):37-41. doi: 10.1111/j.1464-410X.2007.06923.x. Epub 2007 May 4. BJU Int. 2007. PMID: 17488305
-
Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer.BJU Int. 2006 Jul;98(1):50-3. doi: 10.1111/j.1464-410X.2006.06193.x. BJU Int. 2006. PMID: 16831142
-
Percent free PSA as an additional measure in a prostate cancer screen.Clin Lab Sci. 2001 Spring;14(2):102-7. Clin Lab Sci. 2001. PMID: 15625982
-
Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.Eur Urol. 2009 Mar;55(3):563-74. doi: 10.1016/j.eururo.2008.11.040. Epub 2008 Nov 29. Eur Urol. 2009. PMID: 19058905 Review.
-
Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.Curr Opin Urol. 2009 May;19(3):227-31. doi: 10.1097/MOU.0b013e328329a2d0. Curr Opin Urol. 2009. PMID: 19357513 Review.
Cited by
-
Influence of age on seven putative prostate tumor markers: a cohort study in Chinese men.Asian J Androl. 2017 Jul-Aug;19(4):463-467. doi: 10.4103/1008-682X.175787. Asian J Androl. 2017. PMID: 27048780 Free PMC article.
-
Retrospective analysis to describe trends in first-ever prostate-specific antigen (PSA) testing for primary healthcare facilities in the Gauteng Province, South Africa, between 2006 and 2016.BMJ Open. 2022 Mar 21;12(3):e050646. doi: 10.1136/bmjopen-2021-050646. BMJ Open. 2022. PMID: 35314469 Free PMC article.
-
MicroRNA Regulating Glutathione S-Transferase P1 in Prostate Cancer.Curr Pharmacol Rep. 2015 Apr 1;1(2):79-88. doi: 10.1007/s40495-014-0009-3. Curr Pharmacol Rep. 2015. PMID: 25774339 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous